Statins: Major Study Finds Most Side Effects Not Linked to Cholesterol Drugs

Heart disease remains a leading cause of death globally, impacting millions annually. For many, statins are a crucial part of managing cholesterol and reducing cardiovascular risk. However, concerns about potential side effects have led some patients to question or discontinue their treatment. Now, a comprehensive new analysis is challenging long-held beliefs about the safety of these widely prescribed medications.

Reassuring Findings from a Large-Scale Review

Published on February 6, 2026, research led by Oxford Population Health and appearing in The Lancet, provides compelling evidence that most side effects attributed to statins are not, in fact, caused by the drugs themselves. The study, a meta-analysis of 23 randomized trials involving over 123,940 participants, compared statin use to placebo and different statin intensities.

Researchers found remarkably similar rates of reported symptoms between those taking statins and those receiving a placebo. This included conditions like cognitive impairment, memory loss, depression, sleep disturbances, and erectile dysfunction. As Christina Reith, Associate Professor at Oxford Population Health and lead author of the study, explained, “Our study provides reassurance that, for most people, the risk of side effects is greatly outweighed by the benefits of statins.”

What Side Effects Were Actually Linked to Statins?

The analysis examined 66 potential side effects and identified only four with a statistically significant link to statin use. These included a slight increase in abnormal liver blood test results (affecting approximately 0.1% more patients on statins), and very small increases in changes in urine composition and edema (fluid buildup). However, the researchers emphasized that the liver blood test changes did not translate into higher rates of serious liver conditions like hepatitis or liver failure.

Previous research from the same collaborative team had already indicated that most muscle symptoms reported by patients are not attributable to statins. The current study reinforces this finding, showing that only about 1% of individuals experienced muscle symptoms linked to statin therapy during the first year of use, with no additional risk observed after that initial period.

A Small Increase in Blood Sugar Levels

The research also confirmed a slight elevation in blood sugar levels among statin users. This finding suggests that individuals already at risk for developing diabetes may experience an earlier onset of the condition while taking statins. This nuance is important for clinicians to consider when prescribing these medications.

Implications for Patient Care and Information

The findings have significant implications for how statins are perceived and prescribed. Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, highlighted the importance of these results, stating, “These findings are hugely important and provide authoritative, evidence-based reassurance for patients.” He further noted that the study should help prevent unnecessary deaths from cardiovascular disease by countering misinformation surrounding statins.

A key takeaway from the research is the need to revise the information provided to patients about potential statin side effects. Professor Sir Rory Collins, Emeritus Professor of Medicine and Epidemiology at Oxford Population Health, emphasized that current product labels often list side effects based on less reliable studies. “Now that we know that statins do not cause the majority of side effects listed in package leaflets, statin information requires rapid revision to help patients and doctors make better-informed health decisions.”

How the Study Was Conducted

The Cholesterol Treatment Trialists’ (CTT) Collaboration conducted the analysis, pooling data from large-scale, randomized, double-blind trials. This rigorous methodology – where neither participants nor researchers knew who was receiving the statin or placebo – minimized the risk of bias. The trials included over 123,940 participants and followed patients for a median of nearly five years. The list of potential side effects examined was based on those reported for the five most commonly prescribed statins.

The study was funded by the British Heart Foundation, UKRI Medical Research Council, and the Australian National Health and Medical Research Council, with independent oversight provided by an Independent Oversight Panel. This collaborative effort involved researchers from around the world, representing a comprehensive and authoritative assessment of statin safety.

this research offers a valuable contribution to the ongoing conversation about statin therapy, providing evidence-based reassurance for both patients and healthcare providers. While statins are not without potential side effects, the benefits of reducing cardiovascular risk appear to significantly outweigh the risks for the vast majority of individuals.